Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?

Clinical Nephrology

Volumn 70, Issue 6, 2008, Pages 475-484

  Heng, A E ^a   Cellarier, E ^a   Aublet Cuvelier, B ^a   Decalf, V ^a   Motreff, P ^a   Marcaggi, X ^b   Deteix, P ^c   Souweine, B ^c  

^a SERVICE DE RHUMATOLOGIE   (France)

^b CHR de Vichy   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Bicarbonate; Contrast nephropathy; N acetylcysteine; Prevention; Prospective; Randomized

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CONTRAST MEDIUM; CREATINE; IOMEPROL;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HUMAN; HYDRATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 57349190714     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70475     Document Type: Article

References (61)

1. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK. Prospective randomized study of N-acetyleysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Intervent. 2002; 57: 279-283.
2. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a metaanalysis of randomized, controlled trials. Am J Kidney Dis. 2004; 43: 1-9.
3. Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 2004; 44: 12-24.
4. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003; 348: 491-499.
5. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med. 2004; 2: 38-50.
6. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003; 41: 2114-2118.
7. Barrett BJ, Katzberg RW, Thomsen HS et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidot. Invest Radiol. 2006; 41: 815-821.
8. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: metaanalysis. Lancet. 2003; 362: 598-603.
9. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Intervent. 2003; 58: 336-341.
10. Brar SS. MEENA (A Randomized Controlled Trial for the Prevention of Contrast-induced Nephropathy with Sodium Bicarbonate in Persons Undergoing Coronary Angiography). Clin Cardiol. 2007; 30: 416.
11. Briguori C, Manganelli F, Scarpato P et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002; 40: 298-303.
12. Briguori C, Colombo A, Violante A et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004; 25: 206-211.
13. Briguori C, Airoldi F, D'Andrea D et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007; 115: 1211-1217.
14. Carraro M, Malalan F, Antomone R et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol. 1998; 8: 144-147.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creafinine. Nephron. 1976; 16: 31-41.
16. Couchoud C, Pozet N, Laheeurv M, Pouteil-Noble C. Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int. 1999; 55: 1878-1884.
17. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetyleysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002; 89: 356-358.
18. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Céar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant. 2004; 19: 1803-1807.
19. Duong MH, MacKenzie TA, Malenka DJ. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive metaanalysis. Catheter Cardiovase Intervent. 2005; 64: 471-479.
20. Durham JD, Caputo C, Dokko J et al. Arandomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002; 62: 2202-2207.
21. Dussol B, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients Nephrol Dial Transplant, 2006; 21: 2120-2126.
22. Efrati S, Dishy V, Averbukh M et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int. 2003; 64: 2182-2187.
23. Fung JW, Szeto CC, Chan WW et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis. 2004; 43: 801-808.
24. Goldenberg I, Shechter M, Matetzky S et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Fur Heart J. 2004; 25: 212-218.
25. Gomes VO, Poli de Figueredo CE, Caramori P et al. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterisation with an ionic low-osmolality contrast medium: a multicentre clinical trial. Heart. 2005; 91: 774-778.
26. Guru V, Fremes SE. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol. 2004; 62: 77-83.
27. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004; 15: 407-410.
28. Isenbarger DW, Kent SM, O'Malley PG. Metaanalysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol. 2003; 92: 1454-1458.
29. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, McCann WP. Oxygen-free radicals and contrast nephropathy. Am J Kidney Dis. 1998; 32: 64-71.
30. Kay J, Chow WH, Chan TM et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003; 289: 553-558.
31. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol. 2003; 58: 555-560.
32. Kshirsagar AV, Poole C, Mottl A et al. N-acetylcysteine for the prevention of radiocontrast-induced nephropathy: a metaanalysis of prospective controlled trials. J Am Soc Nephrol. 2004; 15: 761-769.
33. Lameire N, Adam A, Becker CR, Davidson C, McCullough PA, Stacul F, Tumlin J, CIN Consensus Working Panel. Baseline renal function screening. Am J Cardiol. 2006; 98: 21K-26K.
34. Levey AS, Greene T, Kusek JW, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000; 11: A0828.
35. Liu R, Nair A, Ix J, Moore DH, Bent S. N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and metaanalysis. J Gen Intern Med. 2005; 20: 193-200.
36. MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D, Jang IK. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography Catheter Cardiovasc Intervent. 2003; 60: 458-461.
37. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004; 44. 1763-1771.
38. Marenzi G, Assanelli E, Marana I et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006; 354: 2773-2782.
39. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tamlin J, CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006; 98: 27K-36K.
40. Merten GJ, Burgess WP Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004; 291: 2328-2334.
41. Miner SE, Dzavik V, Nguyen-Ho P et al. N-acetyleysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004; 148: 690-695.
42. Misra D, Leibowitz K, Gowdu RM, Shapiro M, Khan IA. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a metaanalysis. Clin Cardiol. 2004; 27: 607-610.
43. Mueller C, Buerkle G Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1,620 patients undergoing coronary angioplasty. Arch Intern Med. 2002; 162: 329-336.
44. Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M, Bates ER. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med. 2004; 117: 938-947.
45. Ochoa A, Pellizzon G. Addala S et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Intervent Cardiol. 2004; 17: 159-165.
46. Oldemeyer JB, Biddle WP, Wurdenian RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003; 146: E23.
47. Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N, Aslan O, Badak O. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007; 154: 539-44.
48. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004; 65: 1366-1374.
49. Pannu N, Wiebe N, Tonelli M. Alberta Kidney Disease Network. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006; 295: 2765-2779.
50. Persson PB, Patzak A. Renal hemodynamic alterations in contrast medium-induced nephropathy and the benefit of hydration. Nephrol Dial Transplant. 2005; 20: i2-i5.
51. Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, Sweny P, Hamilton G. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acety1cysteine. J Vase Surg. 2004; 40: 113 6-1141.
52. Recio-Mayoral A, Chaparro M, Prado, B, Cózar R, Méndez I, Banerjee D, Kaski JC, Cubero J, Cruz JM. The renoprotective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol. 2007; 49: 1283-1288.
53. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002; 40: 1383-1388.
54. Solomon R. Contrast media nephropathy - how to diagnose and how to prevent? Nephrol Dial Transplant. 2007; 22: 1812-1815.
55. Solomon RJ Natarajan MK, Doucet S et al. Investigators of the CARE Study. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized, double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007; 115: 3189-3196.
56. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Al1en DA, Timmis GC, O'Neill WW. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast-Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol. 1999; 33: 403-411.
57. Tadros GM, Mouhayar EN, Akinwande AO, Campbell B, Wood C, Blankenship JA. Prevention of radiocontrast-induced nephropathy with N-acetyleysteine in patients undergoing coronary angiography. J Invasive Cardiol. 2003; 15: 311-314.
58. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic contrast agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000; 343: 180-184.
59. Yepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006; 113: 1799-1806.
60. Webb JG Pate GE, Humphries KH et al. A randomized controlled trial of intravenous N-acetyleysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004; 148: 422-429.
61. Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetyleysteine and contrast-induced nephropathy: a metaanalysis of 13 randomized trials. Am Heart J. 2006; 151: 140-145.